News | August 05, 2021
Lyka Labs reports improved set of numbers in Q1FY22
The company has been consistently reducing debt
The company has been consistently reducing debt
Deal for 100 million doses with additional 100 million through 2023
Innovative solutions and a deep understanding of the market makes this a unique combination
It is part of the company’s pain/analgesics portfolio of OTC products
Five seats reserved for Wards of COVID warriors in central MBBS admission
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
It is designed to tackle mental health issues
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Subscribe To Our Newsletter & Stay Updated
